Tyra Biosciences is an oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. Co. is focused on developing a pipeline of selective inhibitors of the Fibroblast Growth Factor Receptor, or FGFR family. Co.'s lead product candidate, TYRA-300, is designed to selectively inhibit Fibroblast Growth Factor Receptor3, with an initial focus on patients with bladder cancer. In addition, Co. has pipeline development programs targeting FGFR2-related cancers, FGFR3-related achondroplasia, REarranged during Transfection kinase, and FGFR4-related cancers.